Abstract
Transgenic mice with neuronal expression of human AD-mutant APP[V7171] in their brain recapitulate robustly the amyloid pathology as seen in Alzheimer’s disease (AD) patients. The AD related pathological phenotype consisting of amyloid plaques and vascular amyloid pathology, develop progressively and relative late in ageing APP transgenic mice, between 10 and 15 months of age. In contrast to the late - and clinically irrelevant - amyloid plaque-pathology, the early cognitive defects and behavioural features are clinically more interesting. This review discusses the generation and in depth phenotypic characterization of both aspects of the APP[V717I] transgenic mice. Attention is focussed on the relation of biochemical data of the different APP fragments and amyloid peptides to the formation of the typical early defects and the late parenchymal and vascular amyloid depositions. The APP[V717I] transgenic mice are a perfect model to characterize and investigate early biochemical and cognitive aspects and a potential resource to define pathological interactions of different factors known to be involved in AD. Finally, any therapeutic intervention can be directly tested and explored in these transgenic mice as excellent pre-clinical models
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Attems J., Jellinger K.A., 2004, Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology — a pilot study. Acta Neuropathol. (Berl). 107: 83–90.
Blennow K., Hampel H., 2003, CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2: 605–613.
Braak H., Braak E., 1991, Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl) 82: 239–259.
De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., Van Leuven F., 1998, Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391: 387–390.
Delacourte A., Buee L., 2000, Tau pathology: a marker of neurodegenerative disorders. Curr. Opin. Neurol. 13: 371–376.
Dewachter I., Van Dorpe J., Smeijers L., Gilis M., Kuiperi C., Laenen I., Caluwaerts N., Moechars D., Checler F., Vanderstichele H. and Van Leuven F., 2000, Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilinl. J. Neurosc. 20: 6452–6458.
Dewachter I., Reverse D., Caluwaerts N., Ris L., Kuiperi C., Van den Haute C., Spittaels K., Umans L., Serneels L., Thiry E., Moechars D., Mercken M., Godaux E., Van Leuven F., 2002, Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J. Neurosci.. 22: 3445–3453.
Dewachter I., Van Leuven F., 2002, Secretases as targets for the treatment of Alzheimer’s disease: the prospects. Lancet Neurol.. 1: 409–416.
Hardy J., 1997, The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc. Natl. Acad. Sci. USA 94: 2095–2097.
May P. and Herz J., 2003, LDL Receptor-related proteins in Neurodevelopment. Traffic, 203: 291–301.
Heutink P., 2000, Untangling tau-related dementia. Hum. Mol. Genet.. 9: 979–986.
Hsiao K., Chapman P., Nilsen S., Eckman C., Hariqaya Y., Younkin S., Yang F., Cole G., 1996, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 174: 99–102.
Ingram E.M., Spillantini M.G., 2002, Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol. Med. 8: 555–562.
Jin L.W., Hua D.H., Shie F.S., Maezawa I., Sopher B., Martin G.M., 2002, Novel tricyclic pyrone compounds prevent intracellular APP C99-induced cell death. J. Mol. Neurosci.. 19: 57–61.
Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M. Tan H., Games D., Lieberburg I., Schenk D., Seubert P., McConlogue L., 1997, Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 94: 1550–1555.
Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E., 2001, Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487–1491.
Li Q.X., Maynard C., Cappai R., McLean C.A., Cherny R.A., Lynch T., Culvenor J.G., Trevaskis J., Tanner J.E., Bailey K.A., Czech C., Bush A.I., Beyreuther K., Masters C.L., 1999, Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer’s disease precursor protein in the hippocampus of aged transgenic mice. J. Neurochem.. 72: 2479–2787.
Liu K., Doms R.W. and Lee V.M.Y., 2002, Glul 1 site cleavage and N-terminally truncated Aβ production upon BACE overexpression. Biochemistry 41: 3128–3136.
Moechars D., Lorent K., De Strooper B., Dewachter I. and Van Leuven F., 1996, Expression in brain of amyloid precursor protein mutated in the α-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J. 15: 1265–1274.
Moechars D., Gilis M., Kuiperi C. Laenen I., Van Leuven F., 1998, Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs. NeuroReport 9: 3561–3564.
Moechars D., Dewachter I., Lorent K., Reversé D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Van Den Haute C., Checler F., Godaux E., Cordell B. and Van Leuven F., 1999a, Early phenotypic changes in transgenic mice that overexpress different mutants of Amyloid Precursor Protein in brain. J. Biol. Chem. 274: 6483–6492.
Moechars D., Lorent K., and Van Leuven F., 1999b, Premature death in transgenic mice that overexpress mutant Amyloid precursor protein is preceded by severe neurodegeneration and apoptosis. Neuroscience 91: 819–830, 1999.
Pedersen W.A., Culmsee C., Ziegler D., Herman J.P., and Mattson M.P., 1999, Aberrant stress response associated with severe hypoglycemia in a transgenic mouse model of Alzheimer’s disease. J. Mol. Neurosci. 13: 159–165.
Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojro E., Prinzen C., Endres K., Hiemke C., Blessing M., Flamez P., Dequenne A., Godaux E., Van Leuven F., Fahrenholz F., 2004, A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer’s disease mouse model. J. Clin. Invest, in press.
Roher A.E., Kuo Y.M., Esh C., Knebel C., Weiss N., Kalback W., Luehrs Childress J.L., Beach T.G., Weller R.O., Kokjohn T.A., 2003, Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer’s disease. Mol. Med.. 9: 112–22.
Selkoe D.J., 2001, Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 81: 741–766.
Selkoe D.J., 2002, Alzheimer’s disease is a synaptic failure. Science. 298: 789–791.
St. George-Hyslop P.H., 2000, Genetic factors in the genesis of Alzheimer’s Disease. Ann. N. Y. Acad. Sci. 924: 1–7.
Terwel D., Dewachter L., Van Leuven F., 2002, Axonal transport, tau protein, and neurodegeneration in Alzheimer’s disease. Nenromolecular Med. 2: 151–165.
Tesseur I., Van Dorpe J., Bruynseels K., Bronfman F., Sciot R., Van Lommel A., Van Leuven F., 2000, Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am. J. Pathol. 157: 1495–1510.
TesseUr I., Van Dorpe J., Spittaels K., Van den Haute C., Moechars D., Van Leuven F., 2000, Expression of human apolipoprotein E4 in neurons causes hyperphosophorylation of protein tau in the brains of transgenic mice. Am. J. Pathol. 156: 951–964.
Tian J., Shi J., Bailey K., Mann D.M., 2003, Negative association between amyloid plaques and cerebral amyloid angiopathy in Alzheimer’s disease. Neurosci. Lett. 352: 137–140.
Van Dorpe J., Smeijers L., Dewachter I., Buyers D., Spittaels K., Van den Haute C., Mercken M., Moechars D., Laenen I., Kuiperi C., Bruynseels K., Tesseur I., Loos R., Vanderstichele H., Checler F., and Van Leuven F., 2000, Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am. J. Pathoi. 157: 1283–98.
Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., Selkoe D.J., 2000, Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20: 1657–1665.
Weller R.O., Massey A., Newman T.A., Hutchings M., Kuo Y.M. and Roher A.E., 1998, Amyloid β accumulates in putative interstitial fluid drainage pathways in Alzheimer’s Disease. Am. J. Pathol. 153: 725–733.
Weller R.O. and Nicoll J.A., 2003, Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol. Res. 25: 611–616.
Willem M., Dewachter I., Smyth N., Van Dooren T., Borghgraef P., Haass C., Van Leuven F., 2004, BACE-1 increases amyloid deposition in brain parenchym but reduces cerebrovascular amyloid angiopathy in BACE × APP[V717I] double transgenic mice. Submitted.
Wong P.C., Zheng H., Chen H., Becher M.W., Sirinathsinghji D.J., Trumbauer M.E., Chen H.Y., Price D.L., Van der Ploeg L.H., Sisodia S.S., 1997, Presenilin 1 is required for Notch 1 and DIIl expression in the paraxial mesoderm. Nature 387: 288–292.
Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., Engstrom L., Pinzon-Ortiz M., Fine J.S., Lee H.J., Zhang L., Higgins G.A., Parker E.M., 2004, Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279:12876–12882.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
van Dooren, T., Dewachter, I., Borghgraef, P., van Leuven, F. (2005). Transgenic Mouse Models for APP Processing and Alzheimer’s Disease: Early and Late Defects. In: Harris, J.R., Fahrenholz, F. (eds) Alzheimer’s Disease. Subcellular Biochemistry, vol 38. Springer, Boston, MA . https://doi.org/10.1007/0-387-23226-5_2
Download citation
DOI: https://doi.org/10.1007/0-387-23226-5_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-23225-6
Online ISBN: 978-0-387-23226-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)